This case illustrates the potential clinical value of combining pigment-targeted picosecond laser therapy with topical JAK inhibition and visible light-specific photoprotection for recalcitrant melasma. The durable remission achieved supports further investigation into anti-inflammatory and photoreactive pathway modulation as adjunctive strategies in melasma management.
Ashkanani et al. (Wed,) studied this question.